Traditional first- or second-line chemotherapy strategies for wild-type epidermal growth factor receptor (EGFR)–expressing non-small-cell lung cancer (NSCLC) include cisplatin- or carboplatin-based combinations; other agents, such as paclitaxel, docetaxel, and gemcitabine, are considered second-line treatments [3,4,5,6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.